Please login to the form below

Not currently logged in
Email:
Password:

Cellerant appoints William Reed as VP clinical development

Will lead development of stem cell-based treatments for blood conditions and cancer

US biotech Cellerant Therapeutics has named Dr William Reed as VP, clinical development.

Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.

He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease.

Dr Reed was also an investigator at Blood Systems Research Institute in San Francisco and a medical director of the Human Islet and Cellular Transplantation Facility at University of California, San Francisco (UCSF).

Ram Mandalam, president and CEO of Cellerant, said:"His extensive experience in paediatric haematology/oncology and transfusion medicine will significantly benefit Cellerant in the development of CLT-008 for cord blood transplantation, leukaemia and acute radiation syndrome applications and the future clinical development of our cancer stem cell programme.”

15th February 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics